Sarah Sloot1,2, Yian A Chen3, Xiuhua Zhao3, Jamie L Weber4, Jacob J Benedict4, James J Mulé5, Keiran S Smalley2,6, Jeffrey S Weber7, Jonathan S Zager2,8,9, Peter A Forsyth10,11, Vernon K Sondak2,8,9, Geoffrey T Gibney12. 1. Department of General Surgery, Groningen University Medical Center, Groningen, The Netherlands. 2. Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida. 3. Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida. 4. Morsani College of Medicine, University of South Florida, Tampa, Florida. 5. Department of Immunology, Moffitt Cancer Center, Tampa, Florida. 6. Department of Tumor Biology, Moffitt Cancer Center, Tampa, Florida. 7. Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York. 8. Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida. 9. Department of Surgery, Morsani College of Medicine, University of South Florida, Tampa, Florida. 10. Department of Neurooncology, Moffitt Cancer Center, Tampa, Florida. 11. Department of Neurooncology, Southern Alberta Cancer Research Institute, Calgary, Alberta, Canada. 12. Georgetown Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC.
Abstract
BACKGROUND: The development of brain metastases is common for systemic treatment failure in patients with melanoma and has been associated with a poor prognosis. Recent advances with BRAF and immune checkpoint therapies have led to improved patient survival. Herein, the authors evaluated the risk of de novo brain metastases and survival among patients with melanoma brain metastases (MBM) since the introduction of more effective therapies. METHODS: Patients with unresectable AJCC stage III/IV melanoma who received first-line systemic therapy at Moffitt Cancer Center between 2000 and 2012 were identified. Data were collected regarding patient characteristics, stage of disease, systemic therapies, MBM status/management, and overall survival (OS). The risk of de novo MBM was calculated using a generalized estimating equation model and survival comparisons were performed using Kaplan-Meier and Cox proportional analyses. RESULTS: A total of 610 patients were included, 243 of whom were diagnosed with MBM (40%). Patients with MBM were younger, with a lower frequency of regional metastasis. No significant differences were noted with regard to sex, BRAF status, or therapeutic class. The risk of de novo MBM was found to be similar among patients treated with chemotherapy, biochemotherapy, BRAF-targeted therapy, ipilimumab, and anti-programmed cell death protein 1/programmed death-ligand 1 regimens. The median OS of patients with MBM was significantly shorter when determined from the time of first regional/distant metastasis but not when determined from the time of first systemic therapy. The median OS from the time of MBM diagnosis was 7.5 months, 8.5 months, and 22.7 months, respectively, for patients diagnosed from 2000 to 2008, 2009 to 2010, and 2011 to the time of last follow-up (P = .002). CONCLUSIONS: Brain metastases remain a common source of systemic treatment failure. The OS for patients with MBM has improved significantly. Further research into MBM prevention is needed. Cancer 2018;124:297-305.
BACKGROUND: The development of brain metastases is common for systemic treatment failure in patients with melanoma and has been associated with a poor prognosis. Recent advances with BRAF and immune checkpoint therapies have led to improved patient survival. Herein, the authors evaluated the risk of de novo brain metastases and survival among patients with melanoma brain metastases (MBM) since the introduction of more effective therapies. METHODS:Patients with unresectable AJCC stage III/IV melanoma who received first-line systemic therapy at Moffitt Cancer Center between 2000 and 2012 were identified. Data were collected regarding patient characteristics, stage of disease, systemic therapies, MBM status/management, and overall survival (OS). The risk of de novo MBM was calculated using a generalized estimating equation model and survival comparisons were performed using Kaplan-Meier and Cox proportional analyses. RESULTS: A total of 610 patients were included, 243 of whom were diagnosed with MBM (40%). Patients with MBM were younger, with a lower frequency of regional metastasis. No significant differences were noted with regard to sex, BRAF status, or therapeutic class. The risk of de novo MBM was found to be similar among patients treated with chemotherapy, biochemotherapy, BRAF-targeted therapy, ipilimumab, and anti-programmed cell death protein 1/programmed death-ligand 1 regimens. The median OS of patients with MBM was significantly shorter when determined from the time of first regional/distant metastasis but not when determined from the time of first systemic therapy. The median OS from the time of MBM diagnosis was 7.5 months, 8.5 months, and 22.7 months, respectively, for patients diagnosed from 2000 to 2008, 2009 to 2010, and 2011 to the time of last follow-up (P = .002). CONCLUSIONS:Brain metastases remain a common source of systemic treatment failure. The OS for patients with MBM has improved significantly. Further research into MBM prevention is needed. Cancer 2018;124:297-305.
Authors: John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies Journal: Cancer Date: 2011-12-16 Impact factor: 6.860
Authors: Ana P Kiess; Jedd D Wolchok; Christopher A Barker; Michael A Postow; Viviane Tabar; Jason T Huse; Timothy A Chan; Yoshiya Yamada; Kathryn Beal Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-05 Impact factor: 7.038
Authors: Kim Margolin; Marc S Ernstoff; Omid Hamid; Donald Lawrence; David McDermott; Igor Puzanov; Jedd D Wolchok; Joseph I Clark; Mario Sznol; Theodore F Logan; Jon Richards; Tracy Michener; Agnes Balogh; Kevin N Heller; F Stephen Hodi Journal: Lancet Oncol Date: 2012-03-27 Impact factor: 41.316
Authors: Tulasi Gummadi; Ben Y Zhang; Sara Valpione; Chul Kim; Lisa A Kottschade; Rajendar K Mittapalli; Vanna Chiarion-Sileni; Jacopo Pigozzo; William F Elmquist; Arkadiusz Z Dudek Journal: Melanoma Res Date: 2015-02 Impact factor: 3.599
Authors: Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian Journal: Cancer Date: 2010-10-19 Impact factor: 6.860
Authors: Sheheryar Kabraji; Jing Ni; Nancy U Lin; Shaozhen Xie; Eric P Winer; Jean J Zhao Journal: Clin Cancer Res Date: 2018-02-06 Impact factor: 12.531
Authors: Hildegard Herman; Csilla Fazakas; János Haskó; Kinga Molnár; Ádám Mészáros; Ádám Nyúl-Tóth; Gábor Szabó; Ferenc Erdélyi; Aurel Ardelean; Anca Hermenean; István A Krizbai; Imola Wilhelm Journal: J Cell Mol Med Date: 2019-02-02 Impact factor: 5.310
Authors: Mark P van Opijnen; Linda Dirven; Ida E M Coremans; Martin J B Taphoorn; Ellen H W Kapiteijn Journal: Int J Cancer Date: 2019-11-23 Impact factor: 7.396